Exubera’s change in control
Pfizer and Sanofi-Aventis are in discussions concerning their partnership for Exubera following a judge's ruling that a "change of control" has occurred in the companies' agreement, Pfizer said during its quarterly earnings call July 20. Pfizer said it now has rights to Exubera under the court's ruling and pursuant to a 1998 agreement between Pfizer and Aventis governing co-marketing of the inhaled insulin. Following Sanofi's acquisition of Aventis in August 2004, Pfizer sued the company in the U.S. and Germany seeking to enforce change of control provisions for Exubera (1"The Pink Sheet" Oct. 25, 2004, p. 17). The Exubera NDA will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on Sept. 8...
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.